Diagnostic and Psychometric Validation of the FRENCH HELP Scale in Hyperemesis Gravidarum (French-HELP)
Severe forms of nausea and vomiting of pregnancy (NVP) are classified as hyperemesis gravidarum (HG). NVP is debilitating in approximately 35% of women impairing daily life and professional activities while negatively affecting family relationships. In 0.3% to 3.6% of pregnancies, the vomiting is intractable and represents the leading cause of hospitalization during the first trimester. Severity of symptoms can sometimes lead women to consider terminating the pregnancy or to decide against future pregnancies.
The most widely used tool for assessing NVP and HG is the PUQE score; it asks three questions regarding nausea, vomiting, and retching, and is scored from 1 to 15. A score of ≥13 classifies NVP as severe. However, the PUQE score does not include questions regarding quality of life, which is a key determinant of HG.
An international definition (the Windsor definition of HG) has been developed, extending beyond mere digestive symptoms. This definition includes: symptom onset in early pregnancy (before 16 weeks of gestation); severe nausea or vomiting; an inability to eat or drink normally; and significant limitation of daily activities or signs of dehydration. This definition aligns better with the full spectrum of symptoms associated with this condition. The US-based Hyperemesis Education and Research (HER) Foundation developed the HELP Score to better assess nausea and vomiting of pregnancy (NVP), particularly severe cases. The tool includes questions regarding the intensity of nausea and vomiting, along with nine additional questions covering hydration, nutrition, treatments and their efficacy, and quality of life. The HELP score ranges from 0 to 60, with scores of 33 to 60 classifying patients as severe; this offers greater scope for assessing levels of severity, and improvement, compared to the PUQE score, which is calculated on a 15-point scale with only 3 points allocated to the severity category.
The HELP score has proved more effective than the PUQE score at identifying patients with severe symptoms requiring intervention, in a study with several methodological limitations, such as reliance on an online questionnaire and a failure to adhere to diagnostic validation standards. Nevertheless, the lack of robust evidence warrants further research using more rigorous methodology to confirm the value of this scoring system.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Stephanie Huberlant
- Telefonnummer: 04 66 68 32 20
- E-post: stephanie.huberlant@chu-nimes.fr
Studiesteder
-
-
-
Alès, Frankrike
- Centre Hospitalier Alès-Cévennes
-
Ta kontakt med:
- Jeanne-Claire SIX
- Telefonnummer: 04 66 78 32 21
- E-post: dr.six@ch-ales.fr
-
Béziers, Frankrike
- CH de Béziers
-
Ta kontakt med:
- Samantha HUET
- Telefonnummer: 04 67 35 76 07
- E-post: samantha.huet@ch-beziers.fr
-
Mende, Frankrike
- CH de Mende
-
Ta kontakt med:
- Agnès PREVOST-FEREY
- E-post: agnesprevostferey@ch-mende.fr
-
Montpellier, Frankrike
- CHU de Montpellier
-
Ta kontakt med:
- Philippe DERUELLE
- Telefonnummer: 04 67 33 64 86
- E-post: p-deruelle@chu-montpellier.fr
-
Nîmes, Frankrike, 30029
- CHU de Nîmes
-
Ta kontakt med:
- Anissa Megzari
- Telefonnummer: 04.66.68.42.36
- E-post: drc@chu-nimes.fr
-
Sète, Frankrike
- CH de Sète
-
Ta kontakt med:
- Angela MORARU
- Telefonnummer: 04 67 46 57 57
- E-post: amoraru@ch-bassindethau.fr
-
Toulouse, Frankrike
- CHU de Toulouse
-
Ta kontakt med:
- Laure CONNAN
- Telefonnummer: 5 67 77 12 33
- E-post: connan.l@chu-toulouse.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- The patient must be a member or beneficiary of a health insurance plan
- Pregnant woman with nausea or vomiting that began during the first trimester of pregnancy (before 16 weeks of gestation) with no other identifiable cause.
- Oral consent given by the participant
Exclusion Criteria:
- The subject is in a period of exclusion determined by a previous study
- The subject unable to provide consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Presence of a secondary cause for nausea and vomiting (hepatitis, pancreatitis, atypical forms of appendicitis, pyelonephritis, adnexal torsion, hyperthyroidism, or chronic treatments known to induce vomiting).
- Presence of any pre-existing medical condition or situation that could cause vomiting (restrictive bariatric surgery, eating disorders).
- Inability to complete the questionnaires (lack of French language comprehension, illiteracy, intellectual disability, etc.).
- Patient enrolled in a study evaluating a treatment intended to address nausea and vomiting.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Women with HG
|
Evaluation of intensity of nausea and vomiting, covering hydration, diet, treatments and their effectiveness, and quality of life.
The HELP score ranges from 0 to 60-with scores of 33 to 60 classifying patients as severe
|
|
Women with severe HG
|
Evaluation of intensity of nausea and vomiting, covering hydration, diet, treatments and their effectiveness, and quality of life.
The HELP score ranges from 0 to 60-with scores of 33 to 60 classifying patients as severe
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area under the curve for the FRENCH HELP score to diagnose hyperemesis gravidarum
Tidsramme: Month 21
|
Month 21
|
|
Area under the curve for the PUQE score to diagnose hyperemesis gravidarum
Tidsramme: Month 21
|
Month 21
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the curve for the FRENCH HELP score to diagnose severe hyperemesis gravidarum
Tidsramme: Month 21
|
Month 21
|
|
|
Area under the curve for the PUQE score to diagnose severe hyperemesis gravidarum
Tidsramme: Month 21
|
Month 21
|
|
|
Discordance rate between FRENCH HELP and PUQE
Tidsramme: Month 21
|
Percentage of women reclassified as severe using the HELP score who were not classified as such using the PUQE score
|
Month 21
|
|
Rate of women whose management would have been altered by using the HELP score
Tidsramme: Month 21
|
percentage (%)
|
Month 21
|
|
Predictive values of FRENCH HELP score on miscarriage
Tidsramme: Month 21
|
Classed as pregnancy loss before 15 weeks of gestation
|
Month 21
|
|
Predictive values of PUQE score on miscarriage
Tidsramme: Month 21
|
Classed as pregnancy loss before 15 weeks of gestation
|
Month 21
|
|
Newborn small for gestational age
Tidsramme: At birth (Max 9 months)
|
Classed as birth weight < 10th percentile
|
At birth (Max 9 months)
|
|
Preterm birth
Tidsramme: At birth (Max 37 weeks)
|
Classed as delivery before 37 weeks of gestation
|
At birth (Max 37 weeks)
|
|
Gestational hypertension
Tidsramme: Before birth (max 9 months)
|
Classed as blood pressure >140 mmHg systolic and/or 90 mmHg diastolic occurring after 20 weeks of gestation
|
Before birth (max 9 months)
|
|
Pre-eclampsia
Tidsramme: Before birth (max Month 9)
|
Classed as gestational hypertension and proteinuria >0.3 g/24 hours
|
Before birth (max Month 9)
|
|
Labor characteristics
Tidsramme: At birth (Max Month 9)
|
Classed as: spontaneous labor, induction, cesarean section, instrumental delivery, postpartum hemorrhage
|
At birth (Max Month 9)
|
|
Fetal heart rate abnormalities during labor
Tidsramme: At birth (max month 9)
|
Yes/no
|
At birth (max month 9)
|
|
Birth weight
Tidsramme: At birth (max 9 months)
|
grams
|
At birth (max 9 months)
|
|
newborn Apgar score < 7
Tidsramme: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
Umbilical cord blood pH
Tidsramme: At birth (max 9 months)
|
At birth (max 9 months)
|
|
|
Umbilical cord blood PCO2
Tidsramme: At birth (max 9 months)
|
mmHg
|
At birth (max 9 months)
|
|
Umbilical cord blood PO2
Tidsramme: At birth (max 9 months)
|
mmHg
|
At birth (max 9 months)
|
|
lactate levels in umbilical arterial blood
Tidsramme: At birth (max 9 months)
|
mmol/L
|
At birth (max 9 months)
|
|
newborns transferred to a neonatal unit
Tidsramme: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
presence of a congenital malformation
Tidsramme: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
presence of depression
Tidsramme: Month 9
|
Measured using the Edinburgh Postnatal Depression Scale - 10 items rated on a scale of 0 to 3, resulting in a total score ranging from 0 to 30.
|
Month 9
|
|
Convergent validity of FRENCH HELP against PUQE score
Tidsramme: Month 21
|
PUQE score - 3 questions regarding nausea, vomiting, and retching, scored from 1 to 15, where score is ≥ 13 is classified as severe.
|
Month 21
|
|
Convergent validity of FRENCH HELP against WHOQOL quality-of-life score
Tidsramme: Month 21
|
WHOQOL-100 questionnaire - 26 questions measuring four domains: physical health, mental health, social relationships, and environment.
Responses to each item are provided using a 5-point Likert scale ranging from 1 (e.g., "Not at all") to 5 (e.g., "Extremely"); these scores are summed and transformed to correspond to a scale ranging from 0 ("poor health-related quality of life") to 100 ("excellent health-related quality of life").
|
Month 21
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Stephanie Huberlant, Centre Hospitalier Universitaire de Nîmes
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AOI GCS/2025/S
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .